Marburg virus-like particles by co-expression of glycoprotein and matrix protein in insect cells induces immune responses in mice

Gai, Weiwei; Zheng, Xiaodong; Wang, Chong; Wang, Hualei; Zhao, Yongkun; Wang, Qi; Wong, Gary; Zhang, Weijiao; Feng, Na; Qiu, Boning; Chi, Hang; Li, Nan; Wang, Tiecheng; Gao, Yuwei; Shan, Jing; Wang, Cuiling; Xia, Xianzhu

doi:10.1186/s12985-017-0869-3

Cited by 8 publications

(6 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PCP, extracted from Poria cocos sclerotium, has been extensively studied as an immunomodulating agent [ 22 – 25 ]. According to previous reports, PCP significantly stimulated antibody responses, enhanced cytokines secretion and exerted protective role against MARV, rabies, and H1N1 [ 15 , 16 , 18 ]. To further elucidate that capacity of PCP to induce antigen-cross presentation and enhance cellular immune response, we used OVA as a model antigen in the present study.…”

Section: Discussionmentioning

confidence: 66%

Poria cocos polysaccharide induced Th1-type immune responses to ovalbumin in mice

Dong

et al. 2021

PLoS ONE

View full text Add to dashboard Cite

In the present study, we evaluated adjuvant potential of Poria cocos polysaccharide (PCP) on the Th1-type immune responses of C57/BL6 mice against ovalbumin (OVA). We first determined the effect of PCP on maturation of murine bone marrow derived dendritic cells (BMDCs), PCP significantly upregulated surface expression of MHCII, CD40, CD80, CD86 and enhanced production of IL-6 and IL-12p40. In addition, PCP affected receptor-mediated endocytosis, but not pinocytosis in BMDCs. Furthermore, OVA + PCP immunization induced specific cytotoxic CD8+ T cell killing of OVA (257–264) peptide pulsed cell. When mice were immunized subcutaneously in a week interval with OVA + PCP. Serum were collected for measuring OVA-specific antibody and splenocytes were harvested for analyzing CD69, IFN-γ ELISpot and cytokines production. The result indicated that OVA-specific IgG, IgG2a and IgG1 antibody levels in serum were significantly elevated by PCP compared with control. PCP increased OVA-specific IFN-γ-secreting CD8+, CD4+ T cells, promoted CD8+ T cell proliferation and up-regulated Th-1 type (IFN-γ, IL-2) cytokine production. In conclusion, data suggest that PCP enhanced cellular immune response and possess potential as a vaccine adjuvant for Th1 immune response.

show abstract

Section: Discussionmentioning

confidence: 66%

Poria cocos polysaccharide induced Th1-type immune responses to ovalbumin in mice

Dong

et al. 2021

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…EBOV vaccines should simultaneously stimulate the specific humoral and cellular immunity essential for effective vaccination [52][53][54]. The protective cellular immune response is associated with the production of several cytokines, including IFN-γ, TNF-α, IL-2, IL-4, and IL-10 [10,55]. Our results showed that SBLP resulted in significant increases in the secretion of these cytokines and that these levels also significantly increased in the presence of the ISA 201VG plus Poly (I:C) adjuvant.…”

Section: Discussionmentioning

confidence: 99%

A Novel Bacterium-Like Particle-Based Vaccine Displaying the SUDV Glycoprotein Induces Potent Humoral and Cellular Immune Responses in Mice

Jiao

Jin

et al. 2019

Viruses

Self Cite

View full text Add to dashboard Cite

Sudan virus (SUDV) causes severe lethal hemorrhagic fever in humans and nonhuman primates. The most effective and economical way to protect against Sudan ebolavirus disease is prophylactic vaccination. However, there are no licensed vaccines to prevent SUDV infections. In this study, a bacterium-like particle (BLP)-based vaccine displaying the extracellular domain of the SUDV glycoprotein (eGP) was developed based on a gram-positive enhancer matrix-protein anchor (GEM-PA) surface display system. Expression of the recombinant GEM-displayed eGP (eGP-PA-GEM) was verified by Western blotting and immunofluorescence assays. The SUDV BLPs (SBLPs), which were mixed with Montanide ISA 201VG plus Poly (I:C) combined adjuvant, could induce high SUDV GP-specific IgG titers of up to 1:40,960 and robust virus-neutralizing antibody titers reached 1:460. The SBLP also elicited T-helper 1 (Th1) and T-helper 2 (Th2) cell-mediated immunity. These data indicate that the SBLP subunit vaccine has the potential to be developed into a promising candidate vaccine against SUDV infections. Viruses 2019, 11, 1149 2 of 15 and receiving unprecedented attention worldwide [4]. Unfortunately, an EVD outbreak occurred again in 2018 in eastern Democratic Republic of Congo and, as of August 2019, a total of 2997 EVD cases had been reported, including 2892 confirmed cases with 1998 deaths (overall case fatality rate of 67%) [5]. Since the first outbreak was reported in 1976, five different species of ebolaviruses, including Ebola virus (EBOV), Sudan virus (SUDV), Reston virus (RESTV), Bundibugyo virus (BDBV), and Taï Forest virus (TAFV,) have been identified and their genomic sequences differ by~35-45% [2]. Excluding EBOV, SUDV has the highest mortality and outbreak rates among the species of ebolaviruses. SUDV has emerged at least six times with average mortality rates of up to 53.76% [6,7]. Multiple vaccines and monoclonal antibodies against EBOV have been developed, but very few of them can effectively prevent and control SUDV infection [8]. Therefore, there is an urgent need to develop a safe and efficacious vaccine against SUDV.The EBOV genome encodes nine structural proteins, including the surface envelope glycoprotein (GP) as the only membrane protein [9]. The mature GP protein forms homotrimers on the surface of infected cells and virions, which is crucial for receptor binding, viral entry, and host immunity induction, making GP an ideal vaccine target [10]. A number of candidate vaccines for EBOV have demonstrated protection against lethal EBOV challenge in animal models and progressed to clinical trials, and most of these vaccines, including DNA vaccines [11], vaccines based on viral vectors, such as recombinant adenovirus [12] and vesicular stomatitis virus (VSV) [13], and protein-based vaccines, such as virus-like particles (VLPs) [14], have been based on GP. Most notably, a number of the candidate vaccines currently under clinical phase evaluation are viral vector-based vaccines [15,16]. While recombinant vesicular stomatitis virus (rVS...

show abstract

“…The Gai team successfully constructed a MARV virus-like particle (VLP). When Poria cocos polysaccharide PCP-II was combined with MARV VLP, the PCP-II group significantly enhanced the specific antibody response and neutralization antibody titer of MARV VLP and improved the immune level of mice [ 82 ]. The protective effect of PCP-II combined with MARV VLP was further evaluated in primate rhesus monkeys.…”

Section: Antiviral Activitymentioning

confidence: 99%

“…Vaccine adjuvant [82,83] Table 2. Antiviral activities of medicinal fungi and their mechanism of action in plant and animal viruses.…”

Section: Poria Cocosmentioning

confidence: 99%

Medicinal Fungi with Antiviral Effect

Zhang

Ling

2022

Molecules

View full text Add to dashboard Cite

Pandemics from various viruses make natural organisms face challenges over and over again. Therefore, new antiviral drugs urgently need to be found to solve this problem. However, drug research and development is a very difficult task, and finding new antiviral compounds is desirable. A range of medicinal fungi such as Ganoderma lucidum and Cordyceps sinensis are widely used all over the world, and they can enhance human immunity and direct anti-virus activities and other aspects to play an antiviral role. Medicinal fungi are used as foods or as food supplements. In this review, the species of medicinal fungi with antiviral activity in recent decades and the mechanism of antiviral components were reviewed from the perspectives of human, animal, and plant viruses to provide a comprehensive theory based on better clinical utilization of medicinal fungi as antiviral agents.

show abstract

Marburg virus-like particles by co-expression of glycoprotein and matrix protein in insect cells induces immune responses in mice

Cited by 8 publications

References 48 publications

Poria cocos polysaccharide induced Th1-type immune responses to ovalbumin in mice

Poria cocos polysaccharide induced Th1-type immune responses to ovalbumin in mice

A Novel Bacterium-Like Particle-Based Vaccine Displaying the SUDV Glycoprotein Induces Potent Humoral and Cellular Immune Responses in Mice

Medicinal Fungi with Antiviral Effect

Contact Info

Product

Resources

About